ReNeuron Group PLC
LSE:RENE
Relative Value
The Relative Value of one RENE stock under the Base Case scenario is 6.791 GBX. Compared to the current market price of 3.375 GBX, ReNeuron Group PLC is Undervalued by 50%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
RENE Competitors Multiples
ReNeuron Group PLC Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
UK |
R
|
ReNeuron Group PLC
LSE:RENE
|
1.9m GBP | 7.7 | -0.4 | 0.5 | 0.5 | |
US |
Abbvie Inc
NYSE:ABBV
|
282.8B USD | 5.2 | 58.7 | 12.8 | 19.5 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
163.1B USD | 5.5 | 43.4 | 18.4 | 30.3 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.8B USD | 11 | 30 | 24.2 | 25.3 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.5B USD | 8.1 | 27.3 | 22.1 | 24.5 | ||
AU |
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36 | 21.7 | 27 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81B USD | 3 | 167.4 | 6.7 | 8.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
46.5B USD | 9 | -7.8 | -8.5 | -7.5 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.1B USD | 3.3 | 27.5 | 14.1 | 17.6 | ||
KR |
Celltrion Inc
KRX:068270
|
40.3T KRW | 18.5 | 75.3 | 46 | 63.4 |